125 results
8-K
EX-99.1
NMTRQ
9 Meters Biopharma, Inc.
29 Nov 22
9 Meters Biopharma Announces Phase 3 Study of Vurolenatide
8:05am
, combined with the product’s safety and tolerability profile, if confirmed in Phase 3, are expected to contribute to improved overall quality of life … ), is a randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy, safety, and tolerability of vurolenatide 50 mg administered
8-K
EX-99.2
NMTRQ
9 Meters Biopharma, Inc.
29 Nov 22
9 Meters Biopharma Announces Phase 3 Study of Vurolenatide
8:05am
degradation time for long half-life (>150 hours) Offers dosing convenience (Q2W) Demonstrates strong safety and tolerability profile ✓ ✓ ✓ ✓ 12
Vurolenatide … status or remnant anatomy Excellent safety and tolerability regardless of remnant anatomy Improved QoL due to lower administration burden and improved
8-K
EX-99.1
NMTRQ
9 Meters Biopharma, Inc.
8 Nov 22
9 Meters Biopharma Provides Business Update and Reports Financial Results for Third Quarter 2022
8:05am
2 VIBRANT study in short bowel syndrome (SBS) reaffirmed the efficacy and safety of vurolenatide and determined the Phase 3 dose and regimen … ) evaluating the safety, efficacy, and tolerability of vurolenatide in adult patients with SBS.
Over the six-week observation period, 50 mg of vurolenatide
8-K
EX-10.1
ng8 x3iq53ot36
6 Oct 22
Entry into a Material Definitive Agreement
4:15pm
8-K
EX-99.2
2anv51 gxyjcim
26 Sep 22
9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT Study and Successful End-of-Phase 2 Meeting with FDA
4:08pm
8-K
EX-99.1
itxrru0mpw 0epnj3l
26 Sep 22
9 Meters Biopharma Announces Positive Final Results from Phase 2 VIBRANT Study and Successful End-of-Phase 2 Meeting with FDA
4:08pm
8-K
EX-99.1
dskeg t10q
15 Aug 22
9 Meters Biopharma Provides Business Update and Reports Financial Results for Second Quarter 2022
7:03am
424B3
9cv0qk go
4 Aug 22
Prospectus supplement
4:17pm
8-K
EX-10.1
apa4a9d2 1p83
30 Jun 22
9 Meters Biopharma Announces Debt Facility to Support Phase 3 Study of Vurolenatide for Short Bowel Syndrome
8:18am
8-K
EX-99.2
13s15l
30 Jun 22
9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome
7:06am
8-K
EX-99.1
n3igx1pyf
30 Jun 22
9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome
7:06am
8-K
EX-99.1
3m0f0sgntig33sf9omma
21 Jun 22
9 Meters Biopharma Announces Interim Analysis of Phase 3 Study of Larazotide for Celiac Disease Does Not Support Trial Continuation
8:02am